These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 28758289)

  • 1. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
    Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the impact of the extended-release/long-acting opioid an-algesics risk evaluation and mitigation strategies on opioid prescrip-tion volume.
    Divino V; Cepeda MS; Coplan P; Maziere JY; Yuan Y; Wade RL
    J Opioid Manag; 2017; 13(3):157-168. PubMed ID: 28829517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States.
    Iwanicki JL; Severtson SG; McDaniel H; Rosenblum A; Fong C; Cicero TJ; Ellis MS; Kurtz SP; Buttram ME; Dart RC
    PLoS One; 2016; 11(12):e0167499. PubMed ID: 27936038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy.
    Black JC; Bau GE; Rosen T; Cepeda MS; Wedin GP; Green JL; Dart RC
    Pain Med; 2020 Jan; 21(1):92-100. PubMed ID: 30877807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits.
    Davis JM; Severtson SG; Bucher-Bartelson B; Dart RC
    Pharmacoepidemiol Drug Saf; 2014 Jan; 23(1):18-25. PubMed ID: 24130046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.
    Cepeda MS; Coplan PM; Kopper NW; Maziere JY; Wedin GP; Wallace LE
    Pain Med; 2017 Jan; 18(1):78-85. PubMed ID: 27373304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER.
    Geoffrey Severtson S; Kreider SED; Amioka EC; Margolin ZR; Iwanicki JL; Dart RC
    Pain Med; 2020 Dec; 21(12):3660-3668. PubMed ID: 33094329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
    Stanos S
    Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse of immediate-release opioids and current approaches to reduce misuse, abuse and diversion.
    Nalamachu SR; Shah B
    Postgrad Med; 2022 May; 134(4):388-394. PubMed ID: 30025214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
    Matthews ML
    J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in abuse and misuse of prescription opioids among older adults.
    West NA; Severtson SG; Green JL; Dart RC
    Drug Alcohol Depend; 2015 Apr; 149():117-21. PubMed ID: 25678441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics.
    Murphy DL; Lebin JA; Severtson SG; Olsen HA; Dasgupta N; Dart RC
    Drug Saf; 2018 Aug; 41(8):787-795. PubMed ID: 29582394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
    Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
    Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers.
    Cicero TJ; Ellis MS; Kasper ZA
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):56-62. PubMed ID: 27594167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in intentional abuse or misuse of benzodiazepines and opioid analgesics and the associated mortality reported to poison centers across the United States from 2000 to 2014.
    Calcaterra SL; Severtson SG; Bau GE; Margolin ZR; Bucher-Bartelson B; Green JL; Dart RC
    Clin Toxicol (Phila); 2018 Nov; 56(11):1107-1114. PubMed ID: 29609498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase your Confidence in Opioid Prescribing: Marketing Messages in Continuing Medical Education Activities on ER/LA Opioids.
    Goodwin B; Lim HD; Butler J; Paglia D; Dempsey MT; O Connor B; Fugh-Berman A
    Pain Physician; 2021 Aug; 24(5):E529-E538. PubMed ID: 34323440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.
    Cicero TJ; Mendoza M; Cattaneo M; Dart RC; Mardekian J; Polson M; Roland CL; Schnoll SH; Webster LR; Park PW
    Postgrad Med; 2019 Apr; 131(3):225-229. PubMed ID: 30794760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.